Immune to Cancer: The CRI Blog
-
CRI Funded Scientist
Ayano Kohlgruber, PhD
While immune checkpoint inhibitors (ICIs) have changed the game by supercharging T cells to fight cancer, for… -
CRI Funded Scientist
Ang Cui, PhD
In the body, immune cells communicate through signaling molecules called cytokines and chemokines to coordinate immune responses…. -
CRI Funded Scientist
Mark Chong, PhD
One of cancer immunotherapy’s toughest balancing acts is how to unleash the immune system against tumors without… -
CRI Funded Scientist
Roberta Zappasodi, PhD
A common feature of tumors that respond to immunotherapy is the presence of effector T cells (Teff),… -
CRI Funded Scientist
Nicolas Vabret, PhD
As people age, changes in the immune system can fuel tumor growth and reduce the body’s ability… -
CRI Funded Scientist
Giorgio Trinchieri, MD
In many patients, cancer disrupts the gut microbiome, leading to chronic inflammation and an immunosuppressive tumor microenvironment… -
CRI Funded Scientist
Filipe Pereira, PhD
Melanoma is a skin cancer whose incidence has risen by 27% annually over the past decade. While… -
CRI Funded Scientist
Ke Pan, PhD
Chordoma is a rare and difficult-to-treat bone cancer whose growth and metastasis is driven in part by… -
CRI Funded Scientist
Allison May, MD
Renal cell carcinoma (RCC) is the most common type of kidney cancer and often treated with surgery…
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.